Cook, CorMatrix Announce Agreement for Engineered Tissue Products

Cook Biotech and CorMatrix Cardiovascular have announced a cross-license agreement to encourage the development of certain cardiovascular medical devices using proprietary extracellular biomaterials held by each company.

CorMatrix, a tissue-engineering and medical device manufacturing company, will develop products for repair of the heart. CorMatrix's potential products include cardiac patch applications for adult and pediatric heart defect repair, myocardial grafts to treat congestive heart failure, as well as applications to stimulate myocardial angiogenesis.

"CorMatrix is focused on the research and development of a proprietary group of extracellular matrix materials for the treatment of cardiac tissue diseases," said Beecher Lewis, president and chief operating officer of CorMatrix. "We are excited about the addition of Cook's widely used biomaterials to our existing technology platform and believe that Cook Biotech's experience in the manufacture of these materials should greatly enhance our development efforts."